The economic burden of CIDP in the United States: A case-control study.
BACKGROUND:Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder of the peripheral nervous system. The economic burden of CIDP is not well understood. OBJECTIVES:To assess the economic and clinical burden of CIDP and to compare the incremental burden relative to a...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC6198979?pdf=render |
id |
doaj-38e90023631a4ee98900135ae0b16412 |
---|---|
record_format |
Article |
spelling |
doaj-38e90023631a4ee98900135ae0b164122020-11-25T01:27:08ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-011310e020620510.1371/journal.pone.0206205The economic burden of CIDP in the United States: A case-control study.Victoria DivinoRajiv MallickMitch DeKovenGirishanthy KrishnarajahBACKGROUND:Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder of the peripheral nervous system. The economic burden of CIDP is not well understood. OBJECTIVES:To assess the economic and clinical burden of CIDP and to compare the incremental burden relative to a matched control group without CIDP. METHODS:This retrospective case-control analysis was conducted using data from the IQVIA Real-World Data Adjudicated Claims. Adults newly diagnosed with CIDP between 7/1/2010 and 6/30/2014 were identified and direct matched to controls without CIDP. Baseline characteristics were assessed and compared over a 6-month pre-index period. Healthcare resource use, costs and clinical characteristics were assessed and compared over a 2-year follow-up. Total cost differences over the 2-year follow-up were compared between matched cohorts using a generalized estimating equation model. RESULTS:The final sample comprised a total of 790 cases matched to 790 controls. Over the 2-year follow-up, cases more frequently experienced neuropathic pain, back pain and osteoarthritis and more commonly utilized opioids, anti-convulsants and anti-depressants. Compared to controls, more cases had ≥1 hospitalization (26.2% vs. 9.0%), and cases had a higher mean number of outpatient prescription fills (62.8 vs. 32.0) and physician office visits (34.7 vs. 13.0) (all p<0.0001). Cases had 7.5x higher mean total costs ($116,330 vs. $15,586, p<0.0001). Important cost drivers were costs for outpatient ancillary, radiology and HCPCS drugs (mean $76,366 vs. $4,292) and costs for inpatient care (mean $16,357 vs. $2,862) (both p<0.0001). Among cases, CIDP therapy (inclusive of both outpatient pharmacy and medical claims) accounted for 51.2% of mean total costs. After further adjusting for baseline clinical characteristics, cases were associated with a 6.1x increase in total costs compared to controls (p<0.0001). CONCLUSIONS:Our findings suggest a substantial clinical and economic burden among patients with CIDP relative to matched controls over a 2-year follow-up.http://europepmc.org/articles/PMC6198979?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Victoria Divino Rajiv Mallick Mitch DeKoven Girishanthy Krishnarajah |
spellingShingle |
Victoria Divino Rajiv Mallick Mitch DeKoven Girishanthy Krishnarajah The economic burden of CIDP in the United States: A case-control study. PLoS ONE |
author_facet |
Victoria Divino Rajiv Mallick Mitch DeKoven Girishanthy Krishnarajah |
author_sort |
Victoria Divino |
title |
The economic burden of CIDP in the United States: A case-control study. |
title_short |
The economic burden of CIDP in the United States: A case-control study. |
title_full |
The economic burden of CIDP in the United States: A case-control study. |
title_fullStr |
The economic burden of CIDP in the United States: A case-control study. |
title_full_unstemmed |
The economic burden of CIDP in the United States: A case-control study. |
title_sort |
economic burden of cidp in the united states: a case-control study. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2018-01-01 |
description |
BACKGROUND:Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder of the peripheral nervous system. The economic burden of CIDP is not well understood. OBJECTIVES:To assess the economic and clinical burden of CIDP and to compare the incremental burden relative to a matched control group without CIDP. METHODS:This retrospective case-control analysis was conducted using data from the IQVIA Real-World Data Adjudicated Claims. Adults newly diagnosed with CIDP between 7/1/2010 and 6/30/2014 were identified and direct matched to controls without CIDP. Baseline characteristics were assessed and compared over a 6-month pre-index period. Healthcare resource use, costs and clinical characteristics were assessed and compared over a 2-year follow-up. Total cost differences over the 2-year follow-up were compared between matched cohorts using a generalized estimating equation model. RESULTS:The final sample comprised a total of 790 cases matched to 790 controls. Over the 2-year follow-up, cases more frequently experienced neuropathic pain, back pain and osteoarthritis and more commonly utilized opioids, anti-convulsants and anti-depressants. Compared to controls, more cases had ≥1 hospitalization (26.2% vs. 9.0%), and cases had a higher mean number of outpatient prescription fills (62.8 vs. 32.0) and physician office visits (34.7 vs. 13.0) (all p<0.0001). Cases had 7.5x higher mean total costs ($116,330 vs. $15,586, p<0.0001). Important cost drivers were costs for outpatient ancillary, radiology and HCPCS drugs (mean $76,366 vs. $4,292) and costs for inpatient care (mean $16,357 vs. $2,862) (both p<0.0001). Among cases, CIDP therapy (inclusive of both outpatient pharmacy and medical claims) accounted for 51.2% of mean total costs. After further adjusting for baseline clinical characteristics, cases were associated with a 6.1x increase in total costs compared to controls (p<0.0001). CONCLUSIONS:Our findings suggest a substantial clinical and economic burden among patients with CIDP relative to matched controls over a 2-year follow-up. |
url |
http://europepmc.org/articles/PMC6198979?pdf=render |
work_keys_str_mv |
AT victoriadivino theeconomicburdenofcidpintheunitedstatesacasecontrolstudy AT rajivmallick theeconomicburdenofcidpintheunitedstatesacasecontrolstudy AT mitchdekoven theeconomicburdenofcidpintheunitedstatesacasecontrolstudy AT girishanthykrishnarajah theeconomicburdenofcidpintheunitedstatesacasecontrolstudy AT victoriadivino economicburdenofcidpintheunitedstatesacasecontrolstudy AT rajivmallick economicburdenofcidpintheunitedstatesacasecontrolstudy AT mitchdekoven economicburdenofcidpintheunitedstatesacasecontrolstudy AT girishanthykrishnarajah economicburdenofcidpintheunitedstatesacasecontrolstudy |
_version_ |
1725106781460365312 |